Here are six things to know:
1. At 60 months of follow-up, the Mobi-C device demonstrated superiority in overall trial success compared to the control anterior cervical discectomy and fusion treatment, which is the traditional option for treating cervical degenerative disc disease.
2. Mobi-C implanted at two contiguous levels showed an overall success rate of 62.8 percent, while the rate of success using ACDF was 34.1 percent.
3. The rate of subsequent surgery at the index level was lower for Mobi-C at 3.8 percent compared to 16.2 percent for ACDF.
4. The mean return to work time was 45.9 days for Mobi-C compared to 66.8 days for ACDF.
5. Mobi-C showed an 82 percent improvement in neck disability index based on success criteria compared to 56.6 percent for ACDF.
6. According to LDR President and CEO Christophe Lavigne, the FDA’s approval of Mobi-C’s labeling updated with five-year safety and efficacy data is another important milestone for LDR.
More articles on devices:
Providence Medical adds surface technology to DTRAX Line: 4 takeaways
Spine Wave launches StaXx XD Xpandable Device: 5 key notes
K2M to introduce Lamellar Titanium Technology: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
